Bioequivalence of Meloxicam Nanocrystal Injection in Healthy Chinese Volunteers
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1467 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Shengling Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Trial Laboratory, Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology; Hubei Clinical …. Hauptthemen laut MEDLINE: Meloxicam, Nanoparticles, Therapeutic Equivalency. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: CSPC Zhongqi Pharmaceutical Technology Co., Ltd., Shijiazhuang, China.
Abstract (Originalsprache)
This single‐center, randomized, open, two‐preparation, single‐dose, two‐period, self‐crossover trial aimed to assess the bioequivalence and safety of the test (T) preparation compared to the reference (R) preparation following intravenous injection in healthy subjects under fasting conditions. Twenty‐four healthy subjects were enrolled in the study and subjects were randomly divided into two groups at a 1:1 ratio and were administered once per period, with an 8‐day washout period. During each period, serum drug concentrations were detected for pharmacokinetic analysis and adverse events were recorded for safety analysis. The 90% confidence intervals for the geometric mean ratios (T:R) of maximum serum concentration, area under the serum concentration‐time curve from time zero to the last measurable concentration, and area under the serum concentration‐time curve from time zero to infinite time fell within the predefined bioequivalence range of 80%‐125%, indicating bioequivalence between the T and R preparation under fasting conditions. Additionally, four subjects (16.7%) experienced five instances of adverse events in the T group, while five subjects (21.7%) experienced five instances of adverse events in the R group. This trial indicated the potential bioequivalence between the T and R products under fasting conditions, based on pharmacokinetic and safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phase I Clinical Trial Laboratory, Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology; Hubei Clinical Research Center for Infectious Diseases; Wuhan Research Center for Com…
- CSPC Zhongqi Pharmaceutical Technology (SJZ) Co., Ltd., Shijiazhuang, China.
Förderung
- CSPC Zhongqi Pharmaceutical Technology Co., Ltd., Shijiazhuang, China
Zitieren
APA
Hu, S., Liu, X., Wan, Q., Zhang, X., & Gong, F. (2024). Bioequivalence of Meloxicam Nanocrystal Injection in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1467
Vancouver
Hu S, Liu X, Wan Q, Zhang X, Gong F. Bioequivalence of Meloxicam Nanocrystal Injection in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1467
BibTeX
@article{Hu2024,
author = {Hu, Shengling and Liu, Xia and Wan, Qinghua and Zhang, Xueyuan and Gong, Fengyun},
title = {Bioequivalence of Meloxicam Nanocrystal Injection in Healthy Chinese Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1467}
}
EUVIMED